Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Syed Sami

Interventional Pain Medicine Saginaw, MI Medical Doctor

NPI 1023345782 CMS profile 1246377

3170 Hallmark Ct, Saginaw, MI 48603

Open in the dashboard

General payments

$2,861

115 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Syed Sami of Saginaw, MI is reported in the CMS Open Payments database as having received $2,861 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $129 4
2022 General $1,340 38
2021 General $935 43
2020 General $204 14
2019 General $254 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Syed Sami
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Syed Sami were reported at $0. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Syed Sami Interventional Pain Medicine median Middle half National median
2019 $254 $684 $216–$2,079 $163
2020 $204 $382 $122–$1,109 $114
2021 $935 $552 $167–$1,554 $132
2022 $1,340 $605 $187–$1,924 $149
2023 $129 $671 $195–$1,915 $160
2024 $0 $684 $206–$1,837 $164
2025 $0 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Abbott Laboratories $1,694 54 payments
  2. AstraZeneca Pharmaceuticals LP $216 4 payments
  3. Sunovion Pharmaceuticals Inc. $170 14 payments
  4. Indivior Inc. $113 6 payments
  5. Orexo US, Inc. $93 7 payments
  6. Pfizer Inc. $71 3 payments
  7. Zimmer Biomet Holdings, Inc. $51 1 payment
  8. Kowa Pharmaceuticals America, Inc. $50 3 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $47 2 payments
  10. Allergan Inc. $41 3 payments
  11. Other $317 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,081 110 payments
  2. Travel and Lodging $694 4 payments
  3. Education $87 1 payment
Products named General payments · program years 2019–2023
  1. PROCLAIM $1,097 24 payments
  2. Proclaim IPG $519 23 payments
  3. BREZTRI $158 3 payments
  4. FARXIGA $104 2 payments
  5. LONHALA MAGNAIR $94 9 payments
  6. Zubsolv $93 7 payments
  7. SUBLOCADE $74 4 payments
  8. GEMTESA $59 4 payments
  9. 3.1mmD MTX Implants $51 1 payment
  10. TRINTELLIX $47 2 payments
  11. Other $772 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

3,367

Median for Family Practice: 1,826

Drug cost

$139,662

Median for Family Practice: $120,094

Branded share of claims

57.6%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 33 $30,584
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 212 $19,581
Zubsolv Buprenorphine Hcl/Naloxone Hcl Brand 28 $17,837
Eliquis Apixaban Brand 17 $16,528
Movantik Naloxegol Oxalate Brand 32 $16,289
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 981 $12,209
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 346 $5,439
Oxycodone Hcl Generic 60 $3,283
Albuterol Sulfate Hfa Albuterol Sulfate Brand 78 $2,645
Morphine Sulfate Er Morphine Sulfate Brand 102 $2,233

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$48,318

Of which drugs: $167

Medicare patients

61

Average age 67

Services billed

1,837

38 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 38%
COPD 34%
Chronic kidney disease 28%
Depression 25%
Ischemic heart disease 18%
Alzheimer's or dementia 0%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 18 1,141 $117

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record